A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects

Abstract

Thirty-two healthy male subjects (8 per cohort) were randomized 6:2 to active:placebo. LSVT-1701, an antistaphylococcal lysin, was administered intravenously as a 6-mg/kg single dose and as 1.5, 3, and 4.5 mg/kg twice daily for 4 days. LSVT-1701 exposure increased in a greater than dose proportional manner and did not accumulate. Treatment-emergent adverse events (TEAEs) were predominantly of mild intensity. The most common TEAEs were chills, pyrexia, headache, infusion site events, cough, rhinorrhea, and increases in C-reactive protein. (This study has been registered at ClinicalTrials.gov under identifier NCT03446053.).

Keywords: LSVT-1701; SAL200; bacteriophage; lysin; pharmacokinetics.

Conflict of interest statement

The authors declare a conflict of interest. M.B.W. and D.B.H. are consultants for Lysovant Sciences.

Figures

FIG 1

Mean (± SD) LSVT-1701 concentrations over time by dose group. LLOQ, lower limit of quantification.